Trial reportPsychological medicine2012
Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.
Trial report in Psychological medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Genetic variation associated with depression in Latin American populations: a systematic review of single-nucleotide variants.Frontiers in psychiatry · 2026Pooled it
- Genome-Wide Meta-Analysis of Longitudinal Alcohol Consumption Across Youth and Early Adulthood.Twin research and human genetics : the official journal of the International Society for Twin Studies · 2015Pooled it
- Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2016Trial
- Insights into Dysregulated GABAergic Synapses and Depression: A Complex and Evolving Relationship.Advances in experimental medicine and biology · 2026Review
- Identifying genetic variants for brain connectivity using Ball Covariance Ranking and Aggregation.Journal of the American Statistical Association · 2025Article
- Genome-wide associations spanning 194 in-hospital drug dosage change phenotypes highlight diverse genetic backgrounds in concurrent drug therapy.Computational and structural biotechnology journal · 2025Article
- The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy.Genes · 2023Review
- Investigating genetic variants for treatment response to selective serotonin reuptake inhibitors in syndromal factors and side effects among patients with depression in Taiwanese Han population.The pharmacogenomics journal · 2023Article
- Deep phenotyping towards precision psychiatry of first-episode depression - the Brain Drugs-Depression cohort.BMC psychiatry · 2023Article
- Precision Medicine Approaches to Mental Health Care.Physiology (Bethesda, Md.) · 2023Review
- Precision Medicine in Antidepressants Treatment.Handbook of experimental pharmacology · 2023Review
- X chromosome-wide association study of quantitative biomarkers from the Alzheimer's Disease Neuroimaging Initiative study.Frontiers in aging neuroscience · 2023Article
- Ancestry-related distribution of Runs of homozygosity and functional variants in Qatari population.BMC genomic data · 2022Article
- Corticosterone-mediated regulation and functions of miR-218-5p in rat brain.Scientific reports · 2022Article
- PtdIns4P restriction by hydrolase SAC1 decides specific fusion of autophagosomes with lysosomes.Autophagy · 2021Article
- CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations-Implication for Drug Safety, Dosing, and Individualized Therapy.Frontiers in genetics · 2021Review
- Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report.The international journal of neuropsychopharmacology · 2020Article
- Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics.Human genomics · 2020Article
- Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample.Advances in therapy · 2018Article
- Delayed Ejaculation: Pathophysiology, Diagnosis, and Treatment.The world journal of men's health · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundUnderstanding individual differences in susceptibility to antidepressant therapy side-effects is essential to optimize the treatment of depression.
methodWe performed genome-wide association studies (GWAS) to search for genetic variation affecting the susceptibility to side-effects. The analysis sample consisted of 1439 depression patients, successfully genotyped for 421K single nucleotide polymorphisms (SNPs), from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Outcomes included four indicators of side-effects: general side-effect burden, sexual side-effects, dizziness and vision/hearing-related side-effects. Our criterion for genome-wide significance was a prespecified threshold ensuring that, on average, only 10% of the significant findings are false discoveries.
resultsThirty-four SNPs satisfied this criterion. The top finding indicated that 10 SNPs in SACM1L mediated the effects of bupropion on sexual side-effects (p = 4.98 × 10(-7), q = 0.023). Suggestive findings were also found for SNPs in MAGI2, DTWD1, WDFY4 and CHL1.
conclusionsAlthough our findings require replication and functional validation, this study demonstrates the potential of GWAS to discover genes and pathways that could mediate adverse effects of antidepressant medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.